Lennox-Gastaut Syndrome Clinical Trial
Official title:
European Registry of Anti-epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS).
This is a registry study, where sites will enter patients with LGS who require a modification in anti-epileptic therapy (either the addition of another anti-epileptic drug, or the change of one drug to another). This will include patients who are started on rufinamide. Patients will be reviewed according to local practice, but it is envisaged that review will occur at approximately one month, three months and six months, and then every six months. Upon entry to the registry baseline details concerning disease severity, diagnosis, prior therapy, and developmental assessment will be recorded. On each subsequent visit the patient (usually through their caregiver) will be asked about current medication, general seizure profile, any seizures deemed to be of medical significance, tolerability, AEs (including suicidal-related events), and healthcare resource utilisation.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04133480 -
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
|
Phase 4 | |
| Recruiting |
NCT02632149 -
Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome
|
Phase 0 | |
| Active, not recruiting |
NCT05626634 -
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
|
Phase 2 | |
| Completed |
NCT01151540 -
A Long Term Extension Study of E2080 in Lennox-Gastaut Patients
|
Phase 3 | |
| Completed |
NCT00552045 -
Epilepsy Phenome/Genome Project
|
||
| Completed |
NCT00004776 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome
|
Phase 3 | |
| Withdrawn |
NCT03254680 -
Turmeric as Treatment in Epilepsy
|
N/A | |
| Completed |
NCT01146951 -
A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)
|
Phase 3 | |
| Completed |
NCT01405053 -
Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
|
Phase 3 | |
| Completed |
NCT02175173 -
Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
|
||
| Completed |
NCT02224573 -
An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
|
Phase 3 | |
| Completed |
NCT00004729 -
Ketogenic Diet for Child Epilepsy and Seizure Control
|
N/A | |
| Terminated |
NCT02815540 -
The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02318537 -
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
|
Phase 3 | |
| Completed |
NCT01160770 -
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome
|
Phase 3 | |
| Completed |
NCT03650452 -
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
|
Phase 2 | |
| Withdrawn |
NCT01370486 -
Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects
|
Phase 4 | |
| Completed |
NCT02731300 -
Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study
|
Phase 4 | |
| Completed |
NCT02224690 -
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
|
Phase 3 |